HER2 (ERBB2) overexpression / amplification

HER2 protein overexpression or ERBB2 gene amplification measured on tumor tissue; used as a predictive marker for HER2-directed therapy in breast, gastric/gastro-esophageal and other carcinomas.

CI-BIO-00000001ERBB2 graph →NCIt C68748 Tumor-agnostic · 2 approval rows

Also calledHER2 · HER2/neu · ERBB2 · HER2-positive · HER2 amplification · HER2-low

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (2)

Trastuzumab Deruxtecan US FDA · Dec 20, 2019 · matched on indication textRegulatory approved
Trastuzumab Deruxtecan US FDA · Dec 20, 2019 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (22)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
HER2-Positive Breast Carcinoma	28	28	—	—	2 / 21 / 0 / 5 / 0
Malignant Colorectal Neoplasm	10	10	—	—	0 / 9 / 0 / 1 / 0
Malignant Breast Neoplasm	5

Derived

Drugs with predictive evidence (27)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
TrastuzumabMonoclonal Antibody	38	38	—	A	31 / 0	Bladder Carcinoma, Cholangiocarcinoma, Endometrial Serous Adenocarcinoma, Gastric Adenocarcinoma +12
LapatinibSmall Molecule	11	11	—	B	10 / 0	Childhood Ependymoma, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, HER2-Positive Breast Carcinoma +2
PertuzumabMonoclonal Antibody	11	11	—	B	10 / 0	Bladder Carcinoma, Cholangiocarcinoma, HER2-Positive Breast Carcinoma, Malignant Biliary Tract Neoplasm +4
AfatinibSmall Molecule	8	8	—	B	7 / 0	HER2-Positive Breast Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Adenocarcinoma
Trastuzumab EmtansineAdc	6	6	—	B	6 / 0	HER2-Positive Breast Carcinoma, Lung Non-Small Cell Carcinoma
CetuximabMonoclonal Antibody	5	—	5	B	0 / 4	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	5	4	1	B	3 / 0	HER2-Positive Breast Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm, Malignant Salivary Gland Neoplasm
DocetaxelSmall Molecule	2	2	—	B	2 / 0	HER2-Positive Breast Carcinoma
NeratinibSmall Molecule	2	2	—	A	2 / 0	HER2-Positive Breast Carcinoma
PictilisibSmall Molecule	2	2	—	D	2 / 0	HER2-Positive Breast Carcinoma, Malignant Breast Neoplasm
Trastuzumab DeruxtecanAdc	2	2	—	A	2 / 0	Malignant Gastric Neoplasm, Solid Neoplasm
A66	1	1	—	D	1 / 0	HER2-Positive Breast Carcinoma
AKTi-1/2	1	1	—	D	1 / 0	Malignant Breast Neoplasm
ErlotinibSmall Molecule	1	—	1	C	0 / 1	Lung Adenocarcinoma
GefitinibSmall Molecule	1	—	1	C	0 / 1	Lung Adenocarcinoma
IrinotecanSmall Molecule	1	1	—	C	1 / 0	Lung Small Cell Carcinoma
MargetuximabMonoclonal Antibody	1	1	—	A	1 / 0	Malignant Breast Neoplasm
MTOR Kinase Inhibitor PP242	1	1	—	D	1 / 0	Malignant Breast Neoplasm
PaclitaxelSmall Molecule	1	1	—	C	1 / 0	Malignant Salivary Gland Neoplasm
PalbociclibSmall Molecule	1	1	—	D	1 / 0	HER2-Positive Breast Carcinoma
PanitumumabMonoclonal Antibody	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
PilaralisibSmall Molecule	1	1	—	D	1 / 0	HER2-Positive Breast Carcinoma
Zoledronic AcidSmall Molecule	1	1	—	C	1 / 0	Malignant Salivary Gland Neoplasm
DacomitinibSmall Molecule	1	1	—	B	—	Lung Non-Small Cell Carcinoma
GemcitabineSmall Molecule	1	1	—	B	—	Malignant Pancreatic Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
Tgx 221	1	1	—	D	—	HER2-Positive Breast Carcinoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (71)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–71 of 71 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification16
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID1687 A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC) PMID 22586653 · Bertotti et al., 2011 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID1993 We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab aft… (full text at CIViC) PMID 28223103 · Jeong et al., 2017 · Open in CIViC	civic
Capecitabine + Cetuximab + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Resistance	1	accepted	EID895 141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and ch… (full text at CIViC) PMID 24146218 · Sclafani et al., 2013 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	2	accepted	EID1688 HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients… (full text at CIViC) PMID 23348520 · Martin et al., 2013 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID7302 In an updated report of a part of the phase 2a MyPathway trial, 57 patients with treatment-refractory, metastatic colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objecti… (full text at CIViC) PMID 30857956 · Meric-Bernstam et al., 2019 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11668 In this clinical study of 38 patients with colorectal cancer (CRC), 28 had CRC with ERBB2 amplification, and were treated with a combination of Pertuzumab and Trastuzumab. The DC rate in the patients … (full text at CIViC) PMID 36315917 · Gupta et al., 2022 · Open in CIViC	civic
Lapatinib + TrastuzumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID1689 Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 week… (full text at CIViC) PMID 27108243 · Sartore-Bianchi et al., 2016 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5981 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Thirty of 1… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Trastuzumab	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1098 This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint. Participants had stage III, IV or recurrent HER2 positive… (full text at CIViC) PMID 19840887 · Fleming et al., 2010 · Open in CIViC	civic
Trastuzumab Deruxtecan	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID7647 In a phase 1 trial, 44 patients with HER2-positive gastric or gastroesophageal junction cancer previously treated with trastuzumab were treated with Trastuzumab Deruxtecan (DS-8201a). The response rat… (full text at CIViC) PMID 31047804 · Shitara et al., 2019 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID5985 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Malignant Uterine NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5986 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Afatinib	Pancreatic Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID962 Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB… (full text at CIViC) PMID 26668065 · Huguet et al., 2016 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Salivary Gland Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID5984 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Trastuzumab	Scrotal Paget DiseaseALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1693 A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable di… (full text at CIViC) PMID 25692060 · Barth et al., 2015 · Open in CIViC	civic
Afatinib	Uterine Corpus Endometrial CarcinomaUNRESOLVED	Predictive	D	Supports Sensitivity Response	2	accepted	EID886 Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gen… (full text at CIViC) PMID 25268372 · Schwab et al., 2014 · Open in CIViC	civic
ERBB2 Overexpression5
Capecitabine + TrastuzumabCombination	Malignant Pancreatic Neoplasm	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID5955 This is Phase II trial of Trastuzumab and capecitabine as first line treatment in patients with IHC 3+ HER2 expressing advanced pancreatic cancer or cancer with HER2 gene amplification of stage IVB. T… (full text at CIViC) PMID 22374460 · Harder et al., 2012 · Open in CIViC	civic
Gemcitabine + TrastuzumabCombination	Malignant Pancreatic Neoplasm	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID5956 Patients with metastatic pancreatic cancer with IHC 2+/3+ HER2 received gemcitabine and Trastuzumab combination. Screening logs demonstrated the rate of HER2 overexpression was 16%. Thirty-four patien… (full text at CIViC) PMID 15581051 · Safran et al., 2004 · Open in CIViC	civic
Paclitaxel + Trastuzumab

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Trastuzumab Deruxtecan	US FDA	Tumor-agnostic	HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated	approved	Dec 20, 2019	openfda
Trastuzumab Deruxtecan	US FDA	Tumor-agnostic	HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )

9 records matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (957)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 456 recruiting · 250 active phase 3 · 4,931 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 957 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04793958	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)	active not recruiting	Phase 3	461	Mirati Therapeutics Inc.INDUSTRY	32	Sep 28, 2026	clinicaltrials
NCT05256225	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma	recruiting	Phase 3	360	National Cancer Institute (NCI)NIH	3	Sep 28, 2026	clinicaltrials
NCT05482893	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)	recruiting	Phase 1 / Phase 2	350	Phanes TherapeuticsINDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT05867251	Study of AVZO-021 in Patients With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	430	Avenzo Therapeutics, Inc.INDUSTRY	2	Sep 28, 2026	clinicaltrials
NCT06586957	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	recruiting	Phase 1	238	NiKang Therapeutics, Inc.INDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT06623422	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	recruiting	Phase 3	680	Merck Sharp & Dohme LLCINDUSTRY	31	Sep 28, 2026	clinicaltrials
NCT06787339	Capecitabine in Low Risk Triple Negative Breast Cancer(Calorite)	recruiting	Phase 2	198	Fudan UniversityOTHER	1	Sep 28, 2026	clinicaltrials
NCT06820463	A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer(AndroMETa-CRC)	recruiting	Phase 2	390	AbbVieINDUSTRY	15	Sep 28, 2026	clinicaltrials
NCT07152782	T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis(THUNDER)	recruiting	Phase 2	202	Fudan UniversityOTHER	1	Sep 28, 2026	clinicaltrials
NCT07621718	Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305)	recruiting	Phase 3	670	Revolution Medicines, Inc.INDUSTRY	2	Sep 28, 2026	clinicaltrials
NCT02595931	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	active not recruiting	Phase 1	66	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT04253964	Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy	recruiting	Phase 2	105	Wake Forest University Health SciencesOTHER	1	Sep 25, 2026	clinicaltrials
NCT04267848	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	recruiting	Phase 3	1,210	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT05132075	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer(KontRASt-02)	active not recruiting	Phase 3	95	Novartis PharmaceuticalsINDUSTRY	25	Sep 25, 2026	clinicaltrials
NCT06103864	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	recruiting	Phase 3	625	AstraZenecaINDUSTRY	24	Sep 25, 2026	clinicaltrials
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	recruiting	Phase 2 / Phase 3	224	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT06312137	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)(TroFuse-019)	recruiting	Phase 3	780	Merck Sharp & Dohme LLCINDUSTRY	31	Sep 25, 2026	clinicaltrials
NCT06369259	Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	recruiting	Phase 2	33	M.D. Anderson Cancer CenterOTHER	1	Sep 25, 2026	clinicaltrials
NCT06377852	The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	recruiting	Phase 3	500	American Society of Clinical OncologyOTHER	1	Sep 25, 2026	clinicaltrials
NCT06385080	A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer(OrigAMI-4)	recruiting	Phase 1 / Phase 2	287	Janssen Research & Development, LLCINDUSTRY	11	Sep 25, 2026	clinicaltrials
NCT07007559	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer(ASPEN-09-03)	recruiting	Phase 2	120	ALX Oncology Inc.INDUSTRY	8	Sep 25, 2026	clinicaltrials
NCT07219212	A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma(LUMIRAY)	recruiting	Phase 1	45	Johnson & Johnson Enterprise Innovation Inc.INDUSTRY	3	Sep 25, 2026	clinicaltrials
NCT07271355	Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial	recruiting	Phase 3	129	City of Hope Medical CenterOTHER	1	Sep 25, 2026	clinicaltrials
NCT07659795	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203)	recruiting	Phase 2	150	Verastem, Inc.INDUSTRY	2	Sep 25, 2026	clinicaltrials
NCT00295893	Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer	active not recruiting	Phase 2	121	City of Hope Medical CenterOTHER	1	Sep 24, 2026	clinicaltrials
NCT03573648	Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer(ImmunoADAPT)	active not recruiting	Phase 2	33	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Sep 24, 2026	clinicaltrials
NCT03716180	DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC	active not recruiting	Phase 1	100	Dana-Farber Cancer InstituteOTHER	1	Sep 24, 2026	clinicaltrials
NCT05863195	Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial	recruiting	Phase 3	408	ECOG-ACRIN Cancer Research GroupNETWORK	1	Sep 24, 2026	clinicaltrials
NCT06018337	A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	active not recruiting	Phase 3	541	DualityBio Inc.INDUSTRY	17	Sep 24, 2026	clinicaltrials
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	recruiting	Phase 1 / Phase 2	134	Neonc Technologies, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT06096844	Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	recruiting	Phase 3	304	National Cancer Institute (NCI)NIH	1	Sep 24, 2026	clinicaltrials
NCT06123338	A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer	recruiting	Phase 2	49	Memorial Sloan Kettering Cancer CenterOTHER	1	Sep 24, 2026	clinicaltrials
NCT07465757	A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)(ALISCA-Lung2)	recruiting	Phase 2	50	Puma Biotechnology, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT07839819	Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies	not yet recruiting	Phase 1 / Phase 2	231	PharmaMarINDUSTRY	4	Sep 24, 2026	clinicaltrials
NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	active not recruiting	N/A	7,458	National Cancer Institute (NCI)NIH	3	Sep 23, 2026	clinicaltrials
NCT04400695	A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2	recruiting	Phase 3	366	RemeGen Co., Ltd.INDUSTRY	1	Sep 23, 2026	clinicaltrials
NCT05489211	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	recruiting	Phase 2	454	AstraZenecaINDUSTRY	14	Sep 23, 2026	clinicaltrials
NCT06102902	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 23, 2026	clinicaltrials
NCT06302621	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors	recruiting	Phase 1	32	Massachusetts General HospitalOTHER	1	Sep 23, 2026	clinicaltrials
NCT03965689	Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	active not recruiting	Phase 2	27	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT04928846	A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	recruiting	Phase 3	768	AbbVieINDUSTRY	32	Sep 22, 2026	clinicaltrials
NCT05215548	Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	recruiting	Phase 2	100	National Taiwan University HospitalOTHER	1	Sep 22, 2026	clinicaltrials
NCT06445062	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	recruiting	Phase 1 / Phase 2	1,130	Revolution Medicines, Inc.INDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT06589804	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment	recruiting	Phase 3	158	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06712316	Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	recruiting	Phase 2 / Phase 3	1,580	BioNTech SEINDUSTRY	22	Sep 22, 2026	clinicaltrials
NCT07146646	Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer	recruiting	Phase 2	27	Case Comprehensive Cancer CenterOTHER	1	Sep 22, 2026	clinicaltrials
NCT07409272	A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer	recruiting	Phase 3	614	Astellas Pharma Global Development, Inc.INDUSTRY	6	Sep 22, 2026	clinicaltrials
NCT07415031	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies	recruiting	Phase 2	170	Mirati Therapeutics Inc.INDUSTRY	20	Sep 22, 2026	clinicaltrials
NCT04543071	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma	active not recruiting	Phase 2	118	Columbia UniversityOTHER	1	Sep 21, 2026	clinicaltrials
NCT04644068	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA)	active not recruiting	Phase 1 / Phase 2	702	AstraZenecaINDUSTRY	14	Sep 21, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (2)

Associated cancers (22)

Drugs with predictive evidence (27)

Predictive evidence items (71)

Approvals mentioning the linked drugs (500)

Active trials (957)

Linked publications (63)